Login to Your Account

After Denufosol Failure, Inspire Ripe to Buy or Be Bought

By Trista Morrison

Tuesday, January 4, 2011
Shares of Inspire Pharmaceuticals Inc. fell 58.7 percent Monday after the firm said cystic fibrosis drug denufosol failed to meet its primary and secondary endpoints in a Phase III trial.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription